Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03210714
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:04.599612+00:00
Published At
2024-09-19T00:00:00+00:00
Record Updated At
2026-04-22
Results Posted At
2024-09-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Malignant Solid Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Childhood Osteosarcoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Glioma", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Refractory Childhood Malignant Germ Cell Tumor", "Refractory Childhood Osteosarcoma", "Refractory Childhood Rhabdomyosarcoma", "Refractory Childhood Soft Tissue Sarcoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Wilms Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-22"
protocolSection.identificationModule.nctId
"NCT03210714"
protocolSection.identificationModule.officialTitle
"NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-09-19"

Study condition terms

  • Advanced Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Ependymoma (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Malignant Germ Cell Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Osteosarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Rhabdomyosarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Hepatoblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Langerhans Cell Histiocytosis (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Glioma (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Recurrent Primary Central Nervous System Neoplasm (protocolSection.conditionsModule.conditions)
  • Recurrent Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Childhood Malignant Germ Cell Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Childhood Osteosarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Childhood Rhabdomyosarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Childhood Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Refractory Ependymoma (protocolSection.conditionsModule.conditions)
  • Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
  • Refractory Hepatoblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Langerhans Cell Histiocytosis (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Glioma (protocolSection.conditionsModule.conditions)
  • Refractory Malignant Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Neuroblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Primary Central Nervous System Neoplasm (protocolSection.conditionsModule.conditions)
  • Refractory Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Wilms Tumor (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.